Umeclidinium/Vilanterol is a combination medication used in this clinical trial to help patients with COPD, which stands for chronic obstructive pulmonary disease. This medication works by relaxing and opening the airways in the lungs, making it easier for patients to breathe. It is being studied to see how it affects the heart’s ability to pump more blood during exercise in patients who also have heart failure.

Chronic Obstructive Pulmonary Disease (COPD) – This is a long-term lung condition that makes it hard to breathe due to airflow blockage. It typically involves symptoms like chronic cough, mucus production, and shortness of breath. Over time, the disease can lead to decreased lung function and increased difficulty in performing physical activities. COPD is often caused by long-term exposure to irritating gases or particulate matter, most commonly from cigarette smoke. The disease progresses gradually, with symptoms worsening over time. It can also lead to complications such as frequent respiratory infections and heart problems.

Heart Failure with Mid-Range Ejection Fraction – This condition occurs when the heart’s left ventricle does not pump blood as efficiently as it should, with an ejection fraction between 35-50%. It can result in symptoms like fatigue, shortness of breath, and fluid retention. The heart’s reduced pumping ability can lead to a buildup of fluid in the lungs and other parts of the body. This type of heart failure is often associated with underlying conditions such as high blood pressure or coronary artery disease. Over time, the heart may become weaker, and symptoms can become more severe. The condition requires careful management to prevent further deterioration of heart function.